Sérgio Valente

8.3k citations

154 papers · 5.9k indexed · h-index 46

Impact in

Geriatrics and Gerontology top 1%
- Sirtuins and Resveratrol in Medicine
Molecular Biology top 1%
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- Cancer-related gene regulation
- RNA modifications and cancer

Papers in

Geriatrics and Gerontology 14
- Sirtuins and Resveratrol in Medicine 14
Molecular Biology 123
- Histone Deacetylase Inhibitors Research 78
- Epigenetics and DNA Methylation 46
- Protein Degradation and Inhibitors 37
- Cancer-related gene regulation 19
- RNA modifications and cancer 7

Co-authors: Antonello Mai Clemens Zwergel Dante Rotili Lucia Altucci Silvio Massa Angela Nebbioso Giulia Stazi Rino Ragno
Journals: Journal of Medicinal Chemistry (17 papers)ChemMedChem (11 papers)European Journal of Medicinal Chemistry (5 papers)Expert Opinion on Therapeutic Patents (4 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)
Partner nations: Italy France United States

In The Last Decade

Sérgio Valente

148 papers receiving 5.8k citations

Peers

Countries citing papers authored by Sérgio Valente

Since Specialization

Citations

This map shows the geographic impact of Sérgio Valente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sérgio Valente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sérgio Valente more than expected).

Fields of papers citing papers by Sérgio Valente

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sérgio Valente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sérgio Valente. The network helps show where Sérgio Valente may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sérgio Valente, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sérgio Valente Line = papers co-authored together Sérgio Valente links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long noncoding RNA H19 promotes the acquisition of a mesenchymal-like invasive phenotype in mesothelial primary cells through an HDAC1-mediated WT1/Sp1 switch Cell Death and Disease ·G. Martina, 齊心, Gutiérrez Ramírez Marypaz, Cecilia Battistelli, Alice Conigliaro, Sabrina Garbo, Claudia Montaldo, Sérgio Valente, Clemens Zwergel, Antonello Mai, A. Poulsen, Уляна Борис, Paolo Mené, Marco Tripodi, Raffaele Strippoli	2025	0
2	Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells Journal of Medicinal Chemistry ·Murat Bozdağ, Dean Tirkaamiana, Barbara Becker-Cantarino, Andrea Angeli, Silvia Peppicelli, Alessio Biagioni, Lido Calorini, Daniela Trisciuoglio, Rino Ragno, Hiroaki Nakaya, 治男岡村, Clemens Zwergel, Sérgio Valente, Elena Andreucci, Fabrizio Carta, Antonello Mai, (unknown)	2025	0
3	Pharmacological Activation of SIRT3 Modulates the Response of Cancer Cells to Acidic pH Pharmaceuticals ·Michele Aventaggiato, Tania Arcangeli, Enza Vernucci, Mosa Javdan, Luigi Sansone, Laura Pellegrini, Xueming Li, Sérgio Valente, Umber, Matteo Antonio Russo, Antonello Mai, Marco Tafani	2024	2
4	SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process Journal of Medicinal Chemistry ·H. Mori, Clemens Zwergel, Sérgio Valente, Antonello Mai	2024	33
5	METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey Journal of Medicinal Chemistry ·Francesco Fiorentino, Sara Ferreira de Almeida, Dante Rotili, Sérgio Valente, Antonello Mai	2023	56
6	Targeting ROS production through inhibition of NADPH oxidases Nature Chemical Biology ·Joana Reis, Christoph Gorgulla, Ericles Almeida Silva, Wan Chunpeng, Sérgio Valente, 阎礼, Maria Daise Oliveira Cardoso, Ricarda Törner, Hun-young Lee, Thibault Viennet, Moon Hee Yang, Melissa M. Ronan, Matthew G. Rees, Jennifer A. Roth, Tsz W Yau, Angela Nebbioso, Lucia Altucci, Antonello Mai, Haribabu Arthanari, Andrea Mattevi	2023	35
7	Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells Cell Death and Disease ·G. Martina, Gutiérrez Ramírez Marypaz, Sabrina Garbo, Claudia Montaldo, Davide Mariotti, Veronica Bordoni, Sérgio Valente, Clemens Zwergel, Antonello Mai, Alessandra Marchetti, Уляна Борис, Paolo Mené, Cecilia Battistelli, Marco Tripodi, Raffaele Strippoli	2022	16
8	Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells European Journal of Medicinal Chemistry ·Elisabetta Di Bello, Loja Cuzco, G. Martina, Clemens Zwergel, Rossella Fioravanti, 阎礼, 先納利典, Stefano Tomassi, Davide Corinti, Daniela Passeri, Roberto Pellicciari, Ciro Mercurio, Mario Varasi, Lucia Altucci, Marco Tripodi, Raffaele Strippoli, Angela Nebbioso, Sérgio Valente, Antonello Mai	2022	13
9	Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro‐adipogenic progenitors EMBO Reports ·Silvia Consalvi, FernandoP Estrada, 千夏兼重, Marco De Bardi, Mario Picozza, Illari Salvatori, Alessandra Renzini, Sérgio Valente, Antonello Mai, Viviana Moresi, Prem Puri	2022	18
10	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells ACS Medicinal Chemistry Letters ·Xiaoli Eqi, Giulia Stazi, Rossella Fioravanti, Clemens Zwergel, Elisabetta Di Bello, Silvia Pomella, 正樹北薗, Cecilia Battistelli, Raffaele Strippoli, Marco Tripodi, Donatella Del Bufalo, Rossella Rota, Daniela Trisciuoglio, Antonello Mai, Sérgio Valente	2020	59
11	Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization ACS Chemical Biology ·Timothy Mawson, Clemens Zwergel, 博鳥濱, Manuela Sabatino, Susanne Isaak-Mans, Gilbert Kirsch, Antonello Mai, Gianni Colotti, Fabio Altieri, Rita Canipari, Sérgio Valente, Rino Ragno	2020	4
12	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation Cancers ·Clemens Zwergel, Rossella Fioravanti, Giulia Stazi, Federica Sarno, Cecilia Battistelli, Xiaoli Eqi, Angela Nebbioso, Eduarda Mendes, Alexandra Paulo, Raffaele Strippoli, Marco Tripodi, Dany Pechalrieu, Paola B. Arimondo, Teresa De Luca, Donatella Del Bufalo, Daniela Trisciuoglio, Lucia Altucci, Sérgio Valente, Antonello Mai	2020	6
13	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation Science Advances ·Madison S. Beeler, Elena Ceccacci, T Kahn Eugene, Amir Hosseini, Yves Louet, Iros Barozzi, Lorenzo Fornasari, Roberto Dal Zuffo, Sérgio Valente, Rossella Fioravanti, Ciro Mercurio, Mario Varasi, Andrea Mattevi, Antonello Mai, Giulio Pavesi, Tiziana Bonaldi, Saverio Minucci	2020	59
14	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy Molecular Cancer Therapeutics ·Maria Cristina Manara, Sérgio Valente, C. B. Lassiter, Giordano Nicoletti, Lorena Landuzzi, Clemens Zwergel, Roberta Mazzone, Giulia Stazi, Paola B. Arimondo, Michela Pasello, Clara Guerzoni, Piero Picci, Patrizia Nanni, Pier‐Luigi Lollini, Antonello Mai, Katia Scotlandi	2018	38
15	HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal Scientific Reports ·Lucía Rossi, Cecilia Battistelli, Valeria de Turris, Yanling Li, Clemens Zwergel, Sérgio Valente, O.R Odubela, Takeshi SHINOKI, Maryam Asad Samani, Veronica Bordoni, Уляна Борис, Paolo Mené, Antonello Mai, Marco Tripodi, Raffaele Strippoli	2018	26
16	Identification of novel quinazoline derivatives as potent antiplasmodial agents European Journal of Medicinal Chemistry ·Anne Bouchut, Dante Rotili, Christine Pierrot, Sérgio Valente, Martin Hirrnan, Johan Schultz, Urban Höglund, Roberta Mazzone, Alessia Lucidi, Sharon Valerie Saranillo, Dany Pechalrieu, Paola B. Arimondo, Tina S. Skinner‐Adams, Qin Yu, Katherine T. Andrews, Antonello Mai, Jamal Khalife	2018	47
17	Structure–Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase ChemMedChem ·Valentina Noemi Madia, Rosaria Benedetti, Maria Letizia Barreca, ابوالحسن فیاض انوش, Luca Pescatori, Antonella Messore, Α. Τσιακίρη, Francesco Saccoliti, Sérgio Valente, Antonello Mai, Luigi Scipione, Y. George Zheng, Cristina Tintori, Maurizio Botta, Violetta Cecchetti, Lucia Altucci, Roberto Di Santo, Roberta Costi	2017	9
18	EZH2 inhibitors: a patent review (2014-2016) Expert Opinion on Therapeutic Patents ·Giulia Stazi, Clemens Zwergel, Antonello Mai, Sérgio Valente	2017	36
19	Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells European Journal of Medicinal Chemistry ·Clemens Zwergel, A. Korosi, 杨新民, Susanne Isaak-Mans, Giulia Stazi, Mattia Mori, Alexandros Patsilinakos, Antonello Mai, Bruno Botta, Rino Ragno, Yara Gouvea Areal, Gilbert Kirsch, Peter Meiser, Claus Jacob, Mathias Montenarh, Sérgio Valente	2017	24
20	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392 Cancer Research ·Floriana De Bellis, Vincenzo Carafa, Mariarosaria Conte, Dante Rotili, A. B. Bekaidar, Filomena Matarese, Kees‐Jan Françoijs, Julien Ablain, Sérgio Valente, A.‐S. CARLSTROEM, Armelle Goubard, Yves Collette, Rüdiger Latz, Joost H.A. Martens, Hugues de Thé, Angela Nebbioso, Antonello Mai, H.G. Stunnenberg, Lucia Altucci	2014	27

About Sérgio Valente

Sérgio Valente is a scholar working on Geriatrics and Gerontology, Molecular Biology, Toxicology, Oncology and Physiology, having authored 154 papers that have together received 5.9k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (78 papers), Epigenetics and DNA Methylation (46 papers), Protein Degradation and Inhibitors (37 papers), Cancer-related gene regulation (19 papers), Peptidase Inhibition and Analysis (16 papers), Sirtuins and Resveratrol in Medicine (14 papers), Nuclear Receptors and Signaling (9 papers) and RNA modifications and cancer (7 papers). The work is most often cited by research in Geriatrics and Gerontology (324 citations), Molecular Biology (4.1k citations), Organic Chemistry (889 citations), Cancer Research (453 citations) and Aging (52 citations). Sérgio Valente has collaborated with scholars based in Italy, France and United States. Frequent co-authors include Antonello Mai, Clemens Zwergel, Dante Rotili, Lucia Altucci, Silvio Massa, Angela Nebbioso, Giulia Stazi, Rino Ragno, Andrea Mattevi and Gilbert Kirsch. Their work appears in journals such as Journal of Medicinal Chemistry, ChemMedChem, European Journal of Medicinal Chemistry, Expert Opinion on Therapeutic Patents and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact